Search

AT2220

GAA to the lysosome, where it can perform its normal function. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

Adrafinil

It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States. … Adrafinil is metabolized to [modafinil].

Methdilazine

It is used in the treatment of various dermatoses to relieve pruritus.

ILY101

ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. … ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.

Tirofiban

It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. … Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery.

PW2101

The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

Etrolizumab

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as

Potassium acetate

Potassium sulfate

Vanoxerine

be abused by humans. … [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use.